Semaglutide Cost: The Same Molecule, Priced Four Ways

What semaglutide costs depends less on the molecule than on the door you walk through. As of August 2026 there are four doors, and they lead to four very different bills. Brand-name Ozempic carries a list price of $997.58 to $1,027.51 per pen — roughly a month of weekly doses — on Novo Nordisk's own pricing page⁶, and every form of Wegovy lists at $1,349.02 per package⁷. Novo's own direct pharmacy undercuts its own list dramatically: Wegovy tablets from $149 a month and pens from $199 self-pay⁷, with commercial insurance bringing the copay as low as $25⁸. And compounded semaglutide through telehealth, across the providers we checked where a true month-to-month figure is knowable, ran a median of about $249 a month, in a range of roughly $125 to $349, as of August 2026 — our own verified checks, with the per-provider rows on the semaglutide provider ranking and in the price transparency index.

The rest of this page is the map: what each door actually costs, what the advertised number leaves out, and why the real unit of cost is a rate per month for as long as you stay on the drug — not a purchase.

What Ozempic, Wegovy and Rybelsus Actually List For

Semaglutide reaches the US market as three Novo Nordisk brands. Ozempic is the once-weekly injection approved for type 2 diabetes, where it was developed and tested first⁵. Wegovy is the same molecule at weight-management doses, the form behind the trial result most people have heard — about 15% average weight loss over 68 weeks at 2.4 mg weekly¹. Rybelsus is the daily 7 mg or 14 mg tablet approved for type 2 diabetes⁴, and Novo's price pages now also list Ozempic tablets at 1.5, 4 and 9 mg — priced per package exactly like the pens⁶. Whether any of this counts as a peptide at all is its own question — see is Ozempic a peptide — and how semaglutide works covers the mechanism the price is attached to.

The list prices are public, printed on the manufacturer's own pages rather than estimated by anyone:

• •Ozempic: $997.58 to $1,027.51 per pen — both figures appear on Novo's page — and the price is the same at every strength, from the 0.25 mg starter pen to the 2 mg pen⁶.
• •Wegovy: $1,349.02 per package, and it is the same figure for the pill, the pen and the higher-dose HD pen⁷.

Note what the manufacturer does that much of the telehealth market does not: it defines the month. Novo's own footnotes state that a month means one box of four pens, or one bottle of 30 tablets⁷. When we audit sellers, the definition of a month is the first thing we check, because in the compounded market it is the thing most often left vague.

What Insurance and Novo's Own Programs Change

A list price predicts very little about what an insured patient pays, and Novo now competes with the compounded market directly. Three programs matter, all read off the manufacturer's own pages in August 2026:

• •Commercial insurance plus the savings offer: as little as $25 a month for Wegovy, capped at $100 of savings per month, with government beneficiaries excluded⁸.
• •NovoCare Pharmacy self-pay — no insurance involved: Wegovy tablets at $149 a month for the 1.5 mg and 4 mg doses (the 4 mg offer runs through August 31, 2026, then $199); Wegovy pens at $199 a month for the first two months on the 0.25 and 0.5 mg starter doses, then $349; and the 7.2 mg HD pen at $399⁷⁸.
• •The Medicare GLP-1 Bridge: $50 a month for eligible Medicare Part D beneficiaries, every dose strength of pen and pill, from July 1, 2026 through December 31, 2027⁸.

Read those numbers against the compounded market's and the comparison gets interesting: brand-name Wegovy, direct from the manufacturer with the approved pen and the approved label, now overlaps the compounded price range. The intro rates are teaser-shaped — $199 becomes $349 after two months, which is a mechanism we would flag on any telehealth seller — but Novo prints the term next to the number, which is exactly the disclosure this site keeps asking the telehealth market for.

What Does Compounded Semaglutide Cost Through Telehealth?

Across the providers on our own ranking where a true month-to-month figure is knowable — meaning a price you can pay this month and stop, not a prepay tier divided by twelve — compounded semaglutide ran a median of about $249 a month, in a range of roughly $125 to $349, as of August 2026. Those are our checks, made against each seller's own live pages, and the per-provider rows with dates are on the semaglutide board and in the price transparency index.

Two things about that range are worth saying plainly. First, it is wide — the most expensive knowable month costs nearly three times the cheapest — and the spread is mostly about business model rather than the drug. Second, the range excludes the sellers where a true monthly figure cannot be established from the public site at all, and there are more of those than a reader would guess. A price you cannot see before the intake is not a low price; it is an unknown one.

Whether compounded semaglutide should be on the menu at all is a regulatory question that has moved several times, and it is not this page's job — is compounded semaglutide still legal and the peptide regulatory tracker cover it. The FDA's standing concerns about unapproved GLP-1 drugs are their own reading: reported dosing errors with compounded injectable semaglutide, and fraudulent compounded products whose labels name pharmacies that do not exist¹⁰.

Why the Advertised "From" Price Understates a Real Month

The single biggest gap in this market is not between sellers. It is between the number a seller advertises and the number a month actually costs, and the mechanism is almost always a commitment.

The prepay ladder. SkinnyRx publishes four terms for every product it sells: injectable semaglutide is $349 if you pay by the month, $299 on four months, $249 on six and $199 only on twelve — and the number on every banner is "As low as $199/mo", the twelve-month rung with no term printed beside it. The ladder itself is unusually honest disclosure; the poster built from its bottom rung is the version that circulates.

The unreconciled number. Oak's own pages carry two different program prices — "as little as $119/month" in its homepage FAQ, "$190/month" on its weight-loss page, one click apart — with nothing on the site saying which one you will be charged, or for what drug and term. (An August 2026 homepage rebuild slimmed the contradiction from three figures to two without closing it.)

The first-month teaser. A "get started for $99" figure prices the act of starting, not the month after it. When the ongoing rate is published nowhere, the advertised number is not a price at all.

The annual rung in monthly clothing. Trimi advertises semaglutide at "$99 per month" — and its own page prints the basis in the same breath: "$1,188 billed once yearly". The plain billed-monthly rate is $175. The gap is honest arithmetic on a dishonest emphasis, and the refund policy makes the up-front commitment final once a clinician signs the prescription.

The storefront the terms contradict. TrimRx's storefront says "Get started for only $179" while its own terms and conditions price the same program at $199 for the first month and $299 for every month after — and its BBB file carries an F rating with a pattern-of-complaints alert. When a seller's storefront and terms disagree, the terms are what you signed.

The dose question left open. Willow prints real prices — semaglutide at $299 a month — but its FAQ says "medication costs vary by dosage and prescription" with no dose table published, so what the number becomes as your dose rises is undisclosed. Its terms also name the five partner pharmacies that may fill your order, one of which carries an April 2025 FDA warning letter.

The house rule this produces: a "from" price is a floor, a floor is not a rate, and the only number worth comparing across sellers is the one you could pay this month and then stop. That is the number our semaglutide ranking is built on, and it is the same discipline we applied to retatrutide's much thinner market.

What Is Included in the Price, and What Is Not?

Two sellers charging the same $249 can cost genuinely different amounts once the rest of the invoice arrives. Before comparing quotes, establish where each of these sits:

• •The consultation. Some include the clinician visit in the monthly price; others bill an intake or visit fee on top, and some charge it even before a prescribing decision is made.
• •Labs. Most compounded-semaglutide sellers require no bloodwork — a convenience, not oversight. A minority bundle real labs: Enhance MD folds metabolic labs at Quest into onboarding, which is part of why its true monthly rate sits at the top of the range.
• •Shipping and supplies. Syringes, alcohol swabs and cold shipping are included at some sellers and itemized at others; a flat shipping fee on a monthly product is a price increase wearing a different name.
• •Membership. A platform or membership fee underneath the medication price is recurring cost that never appears in the advertised figure.

Does the Cost Rise With the Dose?

The approved schedule escalates: Wegovy starts at 0.25 mg weekly and titrates every four weeks toward a maintenance dose of 1.7 or 2.4 mg⁹. So the dose question is really a trajectory question — what does month six cost, not month one?

The brand answer is clean: Novo prices every strength identically, $997.58 to $1,027.51 for any Ozempic pen and $1,349.02 for any Wegovy package⁶⁷, so escalation does not move the list price. The compounded market splits. Dose-tiered pricing — where the advertised starter rate quietly becomes a higher rate as the milligrams rise — is common, and it is the mechanism by which a $199 first month becomes a $300-plus sixth month. The sellers that commit in writing are the exception worth noticing: Enhance MD prints "Same Pricing — All Doses" on its product pages as a stated policy, at a $249 semaglutide sticker on the shortest term — among the highest rates on our ranking, and one of the few that cannot rise with your dose. One cadence caveat: its tiers are billed every four weeks, thirteen charges a year, so that "/mo" sticker works out to about $270 per calendar month.

Dose also interacts with cost in the other direction: the maintenance-dose question — what holds a result rather than produces one — is genuinely open, and it is the honest basis of the low-dose discussion in microdosing tirzepatide, which applies to semaglutide in the same shape. If you are converting a compounded vial's milligrams into syringe units, the arithmetic lives in our semaglutide dosage calculator, semaglutide reconstitution calculator and insulin syringe units converter — the FDA's reported compounded-semaglutide harms cluster exactly there, in self-measured doses drawn from vials¹⁰.

The Cost Is a Rate, Not a Purchase

The last piece of the map is duration, and it is the one the trials speak to directly. In STEP 1, participants lost 14.9% of body weight on average over 68 weeks of weekly 2.4 mg semaglutide¹. In the trial's extension, one year after the drug and the lifestyle support were withdrawn, participants had regained about two-thirds of what they lost². The investigators' own conclusion was that ongoing treatment is required to maintain the improvement².

For a cost page, that finding converts directly into arithmetic: the honest unit is dollars per month multiplied by an open-ended number of months. At our compounded median of $249, a year is about $2,988. At Wegovy's $349 self-pay pen rate, about $4,188. At list price with no coverage, over $16,000⁷. The oral route changes the format, not the math — daily 50 mg oral semaglutide produced weight loss comparable to the injection in its own trial³, and the wider tablet landscape is covered in oral peptides for weight loss. What the drug does to body composition while you pay for it — and what that implies for training — is its own question, covered in semaglutide, tirzepatide and muscle loss.

Bottom Line

Semaglutide has one molecule and at least four prices. Brand list runs about $998 to $1,028 a month for Ozempic and $1,349 for Wegovy before insurance⁶⁷. Novo's own programs sell the approved product for $149 to $399 a month self-pay, $50 on the Medicare bridge, and as little as $25 with commercial coverage⁷⁸. Compounded telehealth ran a median of about $249 a month, $125 to $349, across our August 2026 checks — a range the manufacturer's own direct prices now overlap. The comparison that matters is never advertised figure against advertised figure; it is knowable month against knowable month, with the term, the dose trajectory and the extras made explicit. If tirzepatide is also on your list, tirzepatide vs semaglutide is the head-to-head.

This page is educational and not medical advice. Whether semaglutide is appropriate for you, at what dose and in which form, is a decision for a licensed clinician who knows your history.